Jan 24, 2023

RLS Global AB Tue, Jan 24, 2023 21:40 CET RLS Global AB announces today that Lars Johansson is nominated for election as new Chairman of the Board. Current Chairman Steve Krognes will step down and the change of Chairman is planned for an upcoming extraordinary general shareholder meeting. Lars Johansson is an experienced Managing Director and board professional from the medical device and pharmaceutical industries. He brings significant leadership experience both from Sweden and internationally, and has worked at Johnson & Johnson for close to three decades in positions of increasing seniority and impact. His most recent previous experience includes CEO Nordics at Janssen-Cilag and CEO Nordics at Johnson & Johnson where he had leadership responsibility for several hundreds of people and several hundred million dollars of annual revenues. Lars brings a wealth of commercial experience and proven leadership skills. He is currently serving on the boards of Schain Research AB and ProstaLund AB. “I look forward to joining RLS Global as Chairman and together with the Board and the RLS management team, to accelerate and realize the potential of RLS' unique, patented hypochlorite platform, ChloraSolv. I am convinced that ChloraSolv, which is available in several European markets, will contribute to improved and more efficient care for patients with hard to heal wounds. I am particularly looking forward to working closely with Björn Larsson and our key strategic commercial partners to help drive uptake of ChloraSolv across different geographies”, says Lars Johansson. Steve Krognes has served on the Board of RLS Global since 2018 and as Chairman since 2021. “I am proud of the progress we have jointly achieved at RLS over the years, and in particular bringing an important, new product to patients in the underserved wound care market. With a new, experienced CEO in place and increasing commercial momentum for ChloraSolv through our partnerships, I believe this is a good time to bring in new leadership at the Board. As a significant owner of RLS Global, I remain committed to the company and its success going forward,” says Steve Krognes. The appointment of Lars Johansson as Chairman of the Board is planned for an extra general meeting on February [9], 2023. A formal notice will follow shortly. Lars Johansson is proposed to be elected as Chairman with immediate effect. RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contact person, 24-01-2023 21:40 CET. TRADING PLACE AND CERTIFIED ADVISER: RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget. FOR MORE INFORMATION, PLEASE CONTACT: Björn Larsson, CEO, RLS Global Steve Krognes, Chairman of the Board ABOUT RLS GLOBAL: RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care. RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global